Effect of NK cell immunotherapy on immune function in patients with hepatic carcinoma: A preliminary clinical study

References

• Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5):E359-86; PMID:25220842; https://doi.org/10.1002/ijc.29210
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66(1):7-30; PMID:26742998; https://doi.org/10.3322/caac.21332
   PubMed Web of Science ®Google Scholar
• Verslype C, Rosmorduc O, Rougier P, Group EGW. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(Suppl 7):vii41-8; PMID:22997453; https://doi.org/10.1093/annonc/mds225
   PubMed Web of Science ®Google Scholar
• Hato T, Goyal L, Greten TF, Duda DG, Zhu AX. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology 2014; 60(5):1776-82; PMID:4211962; https://doi.org/10.1002/hep.27246
   PubMed Web of Science ®Google Scholar
• Lim O, Jung MY, Hwang YK, Shin EC. Present and future of allogeneic natural killer cell therapy. Front Immunol 2015; 6:286; PMID:4453480; https://doi.org/10.3389/fimmu.2015.00286
   PubMed Web of Science ®Google Scholar
• Geiger TL, Sun JC. Development and maturation of natural killer cells. Curr Opin Immunol 2016;39:82-9; PMID:4801705; https://doi.org/10.1016/j.coi.2016.01.007
   PubMed Web of Science ®Google Scholar
• Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011; 13(1):98-107; PMID:3760671; https://doi.org/10.3109/14653249.2010.515582
   PubMed Web of Science ®Google Scholar
• Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lewis D, Hippen K, et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 2014; 123(25):3855-63; PMID:4064329; https://doi.org/10.1182/blood-2013-10-532531
   PubMed Web of Science ®Google Scholar
• Hermanson DL, Kaufman DS. Utilizing chimeric antigen receptors to direct natural killer cell activity. Front Immunol 2015;6:195; PMID:4412125; https://doi.org/10.3389/fimmu.2015.00195
   PubMed Web of Science ®Google Scholar
• Romee R, Schneider SE, Leong JW, Chase JM, Keppel CR, Sullivan RP, Cooper MA, Fehniger TA. Cytokine activation induces human memory-like NK cells. Blood 2012; 120(24):4751-60; PMID:3520618; https://doi.org/10.1182/blood-2012-04-419283
   PubMed Web of Science ®Google Scholar
• Keppel MP, Yang L, Cooper MA. Murine NK cell intrinsic cytokine-induced memory-like responses are maintained following homeostatic proliferation. J Immunol 2013; 190(9):4754-62; PMID:3633638; https://doi.org/10.4049/jimmunol.1201742
   PubMed Web of Science ®Google Scholar
• Leong JW, Chase JM, Romee R, Schneider SE, Sullivan RP, Cooper MA, Fehniger TA. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. Biol Blood Marrow Transplant 2014; 20(4):463-73; PMID:3959288; https://doi.org/10.1016/j.bbmt.2014.01.006
   PubMed Web of Science ®Google Scholar
• Luevano M, Madrigal A, Saudemont A. Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy. Cell Mol Immunol 2012;9(4):310-20; PMID:4012863; https://doi.org/10.1038/cmi.2012.17
   PubMed Web of Science ®Google Scholar
• Alici E, Sutlu T, Björkstrand B, Dilber MS. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood 2008(111):3155-62; PMID:18192509; https://doi.org/10.1182/blood-2007-09-110312
   PubMed Web of Science ®Google Scholar
• Koehl U, Sorensen J, Esser R, Zimmermann S, Gruttner HP, Tonn T, Seidl C, Seifried E, Klingebiel T, Schwabe D. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis 2004; 33(3):261-6; PMID:15528141; https://doi.org/10.1016/j.bcmd.2004.08.013
   PubMed Web of Science ®Google Scholar
• Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T, Ohno T. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res 2004; 24(3b):1861-71; PMID:15274367;
   PubMed Web of Science ®Google Scholar
• Sakamoto N, Ishikawa T, Kokura S, Okayama T. Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer. J Transl Med 2015; 13:277; PMID:26303618; https://doi.org/10.1186/s12967-015-0632-8
   PubMed Web of Science ®Google Scholar
• Krause SW, Gastpar R, Andreesen R, Gross C, Ullrich H, Thonigs G, Pfister K, Multhoff G. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial. Clin Cancer Res 2004; 10(11):3699-707; PMID:15173076; https://doi.org/10.1158/1078-0432.CCR-03-0683
   PubMed Web of Science ®Google Scholar
• Handgretinger R, Lang P, Andre MC. Exploitation of natural killer cells for the treatment of acute leukemia. Blood 2016; 127(26):3341-9; PMID:27207791; https://doi.org/10.1182/blood-2015-12-629055
   PubMed Web of Science ®Google Scholar
• Shimasaki N, Coustan-Smith E, Kamiya T, Campana D. Expanded and armed natural killer cells for cancer treatment. Cytotherapy 2016; 18(11):1422-34; PMID:27497701; https://doi.org/10.1016/j.jcyt.2016.06.013
   PubMed Web of Science ®Google Scholar
• Lister J, Rybka WB, Donnenberg AD, deMagalhaes-Silverman M, Pincus SM, Bloom EJ, Elder EM, Ball ED, Whiteside TL. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period. Clin Cancer Res 1995; 1(6):607-14; PMID:9816022
   PubMed Web of Science ®Google Scholar
• Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105:3051-7; PMID:15632206; https://doi.org/10.1182/blood-2004-07-2974
   PubMed Web of Science ®Google Scholar
• Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, Rigatos G, Papamichail M, Perez SA. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother 2010; 59(12):1781-9; PMID:20703455; https://doi.org/10.1007/s00262-010-0904-3
   PubMed Web of Science ®Google Scholar
• Joncker NT, Shifrin N, Delebecque F, Raulet DH. Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment. J Exp Med 2010; 207(10):2065-72; PMID:2947079; https://doi.org/10.1084/jem.20100570
   PubMed Web of Science ®Google Scholar
• Li Y, Yin J, Li T, Huang S, Yan H, Leavenworth J, Wang X. NK cell-based cancer immunotherapy: from basic biology to clinical application. Sci China Life Sci 2015; 58(12):1233-45; PMID:26588912; https://doi.org/10.1007/s11427-015-4970-9
   PubMed Web of Science ®Google Scholar
• Carotta S. Targeting NK cells for anticancer immunotherapy: Clinical and preclinical approaches. Front Immunol 2016; 7:152; PMID:4838611; https://doi.org/10.3389/fimmu.2016.00152
   PubMed Web of Science ®Google Scholar
• Golden-Mason L, Rosen HR. Natural killer cells: multifaceted players with key roles in hepatitis C immunity. Immunol Rev 2013; 255(1):68-81; PMID:23947348; https://doi.org/10.1111/imr.12090
   PubMed Web of Science ®Google Scholar
• Zhang B, Sun T, Xue L, Han X, Zhang B, Lu N, Shi Y, Tan W, Zhou Y, Zhao D, et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 2007; 28(5):1067-73; PMID:17183065; https://doi.org/10.1093/carcin/bgl250
   PubMed Web of Science ®Google Scholar
• Qiu FB, Wu LQ, Lu Y, Zhang S, Zhang BY. Predominant expression of Th1-type cytokines in primary hepatic cancer and adjacent liver tissues. Hepatobiliary Pancreat Dis Int 2007; 6(1):63-6; PMID:17287169
   PubMed Web of Science ®Google Scholar
• Topolcan O, Holubec L, Jr. The role of thymidine kinase in cancer diseases. Exp Opin Ned Giagn 2008; 2(2):129-41; PMID:23485133; https://doi.org/10.1517/17530059.2.2.129
   PubMedGoogle Scholar
• Bolayirli M, Papila C, Korkmaz GG, Papila B, Aydogan F, Karatas A, Uzun H. Serum thymidine kinase 1 activity in solid tumor (breast and colorectal cancer) patients treated with adjuvant chemotherapy. J Clin Lab Anal 2013;27(3):220-6; PMID:23686779; https://doi.org/10.1002/jcla.21587
   PubMed Web of Science ®Google Scholar
• Li HX, Lei DS, Wang XQ, Skog S, He Q. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer. Oncol Rep 2005; 13(1):145-9; PMID:15583816
   PubMed Web of Science ®Google Scholar
• He Q, Fornander T, Johansson H, Johansson U, Hu GZ, Rutqvist LE, Skog S. Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. Anticancer Res 2006; 26(6C):4753-9; PMID:17214336
   PubMed Web of Science ®Google Scholar
• Liu Y, Ling Y, Qi Q, Tang Y, Xu J, Tong Z, Sheng G, Yang Q, Pan Y. Changes in serum thymidine kinase 1 levels during chemotherapy correlate with objective response in patients with advanced gastric cancer. Exp Ther Med 2011; 2(6):1177-81; PMID:22977640; https://doi.org/10.3892/etm.2011.338
   PubMed Web of Science ®Google Scholar
• Liao Y, Wang SY, Meng XY, Yang J, Shi MJ, Liu HL, Chen FF, Xiong B. Circulating tumor cells in breast cancer and its association with tumor clinicopathological characteristics: a meta-analysis. Med Oncol 2014; 31(12):343; PMID:25412938; https://doi.org/10.1007/s12032-014-0343-7
   PubMed Web of Science ®Google Scholar
• Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005; 106(1):376-83; PMID:1895123; https://doi.org/10.1182/blood-2004-12-4797
   PubMed Web of Science ®Google Scholar
• Zhang M, Daniel S, Huang Y, Chancey C, Huang Q, Lei YF, Grinev A, Mostowski H, Rios M, Dayton A. Anti-West Nile virus activity of in vitro expanded human primary natural killer cells. BMC immunology 2010; 11:3; PMID:2822749; https://doi.org/10.1186/1471-2172-11-3
   PubMed Web of Science ®Google Scholar
• Witt CS, Christiansen FT. The relevance of natural killer cell human leucocyte antigen epitopes and killer cell immunoglobulin-like receptors in bone marrow transplantation. Vox Sang 2006; 90(1):10-20; PMID:16359351; https://doi.org/10.1111/j.1423-0410.2005.00712.x
   PubMed Web of Science ®Google Scholar
• Forte P, Baumann BC, Schneider MK, Seebach JD. HLA-Cw4 expression on porcine endothelial cells reduces cytotoxicity and adhesion mediated by CD158a+ human NK cells. Xenotransplantation 2009;16(1):19-26; PMID:19243557; https://doi.org/10.1111/j.1399-3089.2009.00510.x
   PubMed Web of Science ®Google Scholar